The European Commission denied on Thursday that the EU’s vaccination strategy against covid-19 in the next few years will be completely dependent on Pfizer and BioNTech It has not ruled out the opportunity to start negotiations with other laboratories, and even start negotiations with laboratories that develop technologies other than messenger RNA or mRNA, such as Janssen or AstraZeneca.
This is how the community executive responded to the media’s questions about the news published by the Italian newspaper “La Stampa” at the press conference, which ensures that Brussels has decided not to renew the contract with it. AstraZeneca and Janssen, Adenovirus vector vaccine.
He said: “Yesterday, President von Lehn announced that it would start negotiations with PfIzer and BioNTech to purchase more mRNA vaccines from these companies, but this does not mean that we will not consider signing other contracts with companies that use other technologies.” Stefan de Keersmaecker, Health Spokesperson of the European Commission.
The spokesperson therefore recalled that he was already negotiating with the two laboratories with a view to 1.8 billion vaccine doses received by 2022 and 2023In order to prevent the possible emergence of new mutations and the potential need to strengthen population immunity.
The main spokesperson of the European Commission, Éric Mamer, also expressed his views. He acknowledged that Brussels has always been committed to the success of mRNA technology and this fact when “thinking before”. Pfizer and BioNTech are delivering, But “this has no effect on other contracts that the committee may sign in the future”,
In addition, Brussels has shown confidence in the goals that the EU will achieve The goal of 70% vaccination by summer Despite the problems of AstraZeneca and Janssen, their adult population still accounts for half of the total population. To achieve this goal, De Keersmaecker reviewed recent agreements with Pfizer and BioNTech to facilitate the distribution of 50 million doses, which are scheduled to be distributed by the end of this year.
“We believe that we are achieving the goal of vaccinating 70% of the adult population. Of course, The important thing is to deliver on time “And member states get vaccinated as soon as they receive the dose,” he pointed out.
Regarding the recent suspension of the distribution of Janssen’s dose, before waiting for new conclusions about his thrombotic incident in the United States, a spokesperson for the European Community said that the committee is in contact with the company and with other pharmaceutical companies. It has an agreement.
In this sense, he emphasized that the “safe and effective” vaccines received by EU countries are “fundamental”, which is why he defended the necessity of waiting for vaccination. Evaluation by the European Medicines Agency (EMA) on Janssen serum. Regarding the fact that Denmark has given up vaccination against AstraZeneca, the European Commission is limited to reviewing that the design of the campaign is a national capability, but insists that 27 campaigns must adopt a coordinated approach based on scientific evidence.
Therefore, in accordance with the consent of the Minister of Health last week, the community executive has sent a letter to EMA asking it to continue to investigate the link between the Anglo-Swedish vaccine and the rare blood clot.European authorities also sent letters to all capitals Submit relevant data to EMA so that agents can analyze more specific issues As a group of people who may be more susceptible to these events.